A novel cell-penetrating peptide TAT-A1 delivers siRNA into tumor cells selectively (2013)
Sequence: YGRKKRRQRRRGWFLLTM
| Experiment Id | EXP001430 |
|---|---|
| Paper | A novel cell-penetrating peptide TAT-A1 delivers siRNA into tumor cells selectively |
| Peptide | TAT-A1 (VEGFR1-targeted TAT) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 10 µM peptide in complexation (typical); peptide-only uptake tested 0.1–10 µM |
| Rna Concentration | 50 nM siRNA (uptake + knockdown assays) |
| Mixing Ratio | Electrostatic noncovalent complexes; typical peptide:siRNA molar ratio 30:1 (screened 10:1–40:1); peptide 10 µM with siRNA 50 nM; incubated 30 min at 37°C |
| Formulation Format | Noncovalent CPP/siRNA electrostatic complexes (aggregates/nanoparticles) |
| Formulation Components | TAT-A1 (VEGFR1-targeted TAT) + siRNA |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HepG2 (human hepatocarcinoma; VEGFR1-high) |
| Animal Model | |
| Administration Route | |
| Output Type | GAPDH mRNA/protein knockdown (qPCR + Western blot) |
| Output Value | 71 |
| Output Units | |
| Output Notes | GAPDH mRNA decreased ~44% at 24 h and ~71% at 48 h after treatment (50 nM siRNA; TAT-A1:siRNA 30:1). GAPDH protein suppression was also observed; efficacy comparable to (24 h) and stronger than (48 h) Lipofectamine 2000 in their assay. |
| Toxicity Notes | |
| Curation Notes |